FOR IMMEDIATE RELEASE

Bayer, GlaxoSmithKline and the NFL Announce Legend
Mike Ditka to be Spokesperson for
National Men’s Health Education Campaign

Hall of Famer Will Help Launch “Tackling Men’s Health” Program

West Haven, CT, Philadelphia, PA and New York, NY, July 31, 2003 – Bayer Pharmaceuticals Corporation (Bayer), GlaxoSmithKline (GSK) and the National Football League (NFL) announced today Mike Ditka as the spokesperson for the NFL’s national men’s health education campaign.  The program will be called “Tackling Men’s Health,” and will address critical health issues impacting millions of men.

“Tackling Men’s Health” is an integral component of the groundbreaking multi-year sponsorship agreement with Bayer and GSK that was recently announced by the NFL. This represents the first multi-year official sponsorship for the NFL with pharmaceutical companies. Bayer and GSK will be “Proud Sponsors of the NFL” which includes exclusive rights in the men’s health category.. Bayer and GSK signed a co-promotion and co-development agreement for LEVITRA â (vardenafil HCI), which is an investigational new drug awaiting approval from FDA.

“It’s an honor for me to be associated with such an important program that will generate awareness of critical men’s health issues that affect guys like me,” said Ditka. “I’ve had experience with some health issues in my own life.  I look forward to the challenge of using that experience to motivate men to take action and help take care of themselves.  Taking care of your health should be a part of everyone’s game plan.”

Ditka, one of the most popular and recognizable personalities in sports, played 12 years in the NFL as a talented and versatile tight end. He served as a coach in the NFL for 14 years, leading the Chicago Bears to victory in Super Bowl XX. In 1988 he was inducted into the Pro Football Hall of Fame. Today he is a successful restaurateur, broadcaster and public speaker.

 “Mike Ditka is an excellent choice to be a spokesperson for the Tackling Men’s Health initiative,” said John Collins, NFL Senior Vice President of Marketing & Sales.  “He’s a legend, a Hall of Famer, who commands tremendous respect from our fans. He understands the health issues that this program will address and has a great ability to communicate – as he has proven both on and off the playing field.”

About Bayer Pharmaceuticals Corporation
Bayer Pharmaceuticals Corporation is part of the worldwide operations of Bayer HealthCare, a subgroup of Bayer AG. Bayer HealthCare is one of the world's leading innovators in the health care and medical products industry.

Bayer HealthCare combines the global activities of the business groups of Bayer AG in the fields of Animal Health, Biological Products, Consumer Care, Diagnostics and Pharmaceuticals. More than 34,000 employees support the worldwide operations of Bayer HealthCare.

Our work at Bayer HealthCare is to discover and manufacture innovative products for the purpose of improving human and animal health worldwide. Our products enhance well-being and quality of life by diagnosing, preventing and treating disease.

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

About GSK
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are discussed under risk factors in the Company's Preliminary Announcement of Results for the Year Ended 31st December 2002.
 

Contacts:
Michael Fleming                                        Lara Crissey
GlaxoSmithKline                                        Bayer HealthCare
215-751-7074                                            203-812-6558
michael.d.fleming@gsk.com                          lara.crissey.b@bayer.com

Brian McCarthy                                         Rob Bronfeld
National Football League                          Alan Taylor Communications
212-450-2069                                           212-714-1280, ext. 291
mccarthyb@nfl.com                                     rob@alantaylor.com

#  #  #